PUBLISHER: Allied Market Research | PRODUCT CODE: 1566981
PUBLISHER: Allied Market Research | PRODUCT CODE: 1566981
Vinpocetine Market By Product Type (Tablet, Injection) , By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Vinpocetine Market
The vinpocetine market was valued at $0.2 billion in 2023 and is projected to reach $0.3 billion by 2033, growing at a CAGR of 3.5% from 2024 to 2033.
Vinpocetine is a synthetic chemical that holds resemblance with a natural compound derived from the plant Vinca minor. The compound is a multi-action agent used to treat various conditions and diseases, including head injuries, stroke, dementia during Parkinson's disease, age-related memory loss, and Alzheimer's disease. The primary action mechanism of vinpocetine involves the enhancement of cerebral blood flow, resulting in improved nutrient and oxygen delivery to the brain. Owing to its remarkable safety profile, the chemical has been made available in the form of dietary supplement for enhanced cognition and memory.
Increase in the prevalence of cognitive disorders, particularly due to exponential growth in the elderly population has significantly driven the growth of the vinpocetine market. In addition, with rising awareness regarding the timely prevention of neurodegenerative diseases, individuals are beginning the consumption of dietary supplements as a precautionary measure, thereby boosting the demand for vinpocetine. The expanding landscape of dietary supplements augments the growth of the market notably. Currently, explorations regarding the applications of vinpocetine beyond its cognitive support are trending. The chemical has been tested for the treatment of diverse conditions such as atherosclerosis and injured alveolar epithelial cells in pulmonary fibrosis. Such expansion of applications is projected to present new segments for market development.
However, the chemical faces different regulatory hurdles in several countries owing to its classification and efficacy, which restrains the widespread growth of the market. Furthermore, several alternative and competent alternatives are available for the treatment of Alzheimer's and dementia, hampering market development. For instance, the U.S. Food and Drug Administration and recently approved the efficacy of a novel drug-lecanemab-an anti-amyloid monoclonal antibody, for the treatment of dementia. The drug particularly targets the elementary causes of the disease by binding to amyloid-beta plaques, the hallmark of the disease. Different studies have advocated for the effectiveness of lecanemab, presenting challenges for the expansion of the vinpocetine market.
Segment Review
The vinpocetine market is segmented into product type, distribution channel, and region. On the basis of product type, the market is bifurcated into tablet and injection. As per distribution channel, it is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the tablet segment acquired a high stake in the market in 2023.
As per distribution channel, the retail pharmacies segment accounted for a high market share in 2023.
Region wise, North America holds a dominant position in the vinpocetine market.
Competition Analysis
The leading players operating in the global vinpocetine market include Northeast Pharmaceutical Group Co., Ltd., Gedeon Richter, COVEX, Runhong, Liaoning Zhiying, Sun Pharmaceuticals Industries Ltd, Welman, and Micro Labs Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
- Tablet
- Injection
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Northeast Pharmaceutical Group Co., Ltd.
- COVEX
- Runhong
- Liaoning Zhiying
- Sun Pharmaceuticals Industries Ltd
- Welman
- Micro Labs Ltd
- Gedeon Richter Plc.
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: VINPOCETINE MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Tablet
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Injection
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
CHAPTER 5: VINPOCETINE MARKET, BY DISTRIBUTION CHANNEL
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Distribution Channel
- 5.2. Retail Pharmacies
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Hospital Pharmacies
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Online Pharmacies
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
CHAPTER 6: VINPOCETINE MARKET, BY REGION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Product Type
- 6.2.3. Market Size and Forecast, By Distribution Channel
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Vinpocetine Market
- 6.2.5.1. Market Size and Forecast, By Product Type
- 6.2.5.2. Market Size and Forecast, By Distribution Channel
- 6.2.6. Canada Vinpocetine Market
- 6.2.6.1. Market Size and Forecast, By Product Type
- 6.2.6.2. Market Size and Forecast, By Distribution Channel
- 6.2.7. Mexico Vinpocetine Market
- 6.2.7.1. Market Size and Forecast, By Product Type
- 6.2.7.2. Market Size and Forecast, By Distribution Channel
- 6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Product Type
- 6.3.3. Market Size and Forecast, By Distribution Channel
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Vinpocetine Market
- 6.3.5.1. Market Size and Forecast, By Product Type
- 6.3.5.2. Market Size and Forecast, By Distribution Channel
- 6.3.6. France Vinpocetine Market
- 6.3.6.1. Market Size and Forecast, By Product Type
- 6.3.6.2. Market Size and Forecast, By Distribution Channel
- 6.3.7. UK Vinpocetine Market
- 6.3.7.1. Market Size and Forecast, By Product Type
- 6.3.7.2. Market Size and Forecast, By Distribution Channel
- 6.3.8. Italy Vinpocetine Market
- 6.3.8.1. Market Size and Forecast, By Product Type
- 6.3.8.2. Market Size and Forecast, By Distribution Channel
- 6.3.9. Spain Vinpocetine Market
- 6.3.9.1. Market Size and Forecast, By Product Type
- 6.3.9.2. Market Size and Forecast, By Distribution Channel
- 6.3.10. Rest of Europe Vinpocetine Market
- 6.3.10.1. Market Size and Forecast, By Product Type
- 6.3.10.2. Market Size and Forecast, By Distribution Channel
- 6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Product Type
- 6.4.3. Market Size and Forecast, By Distribution Channel
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Vinpocetine Market
- 6.4.5.1. Market Size and Forecast, By Product Type
- 6.4.5.2. Market Size and Forecast, By Distribution Channel
- 6.4.6. China Vinpocetine Market
- 6.4.6.1. Market Size and Forecast, By Product Type
- 6.4.6.2. Market Size and Forecast, By Distribution Channel
- 6.4.7. Australia Vinpocetine Market
- 6.4.7.1. Market Size and Forecast, By Product Type
- 6.4.7.2. Market Size and Forecast, By Distribution Channel
- 6.4.8. India Vinpocetine Market
- 6.4.8.1. Market Size and Forecast, By Product Type
- 6.4.8.2. Market Size and Forecast, By Distribution Channel
- 6.4.9. South Korea Vinpocetine Market
- 6.4.9.1. Market Size and Forecast, By Product Type
- 6.4.9.2. Market Size and Forecast, By Distribution Channel
- 6.4.10. Rest of Asia-Pacific Vinpocetine Market
- 6.4.10.1. Market Size and Forecast, By Product Type
- 6.4.10.2. Market Size and Forecast, By Distribution Channel
- 6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Product Type
- 6.5.3. Market Size and Forecast, By Distribution Channel
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Vinpocetine Market
- 6.5.5.1. Market Size and Forecast, By Product Type
- 6.5.5.2. Market Size and Forecast, By Distribution Channel
- 6.5.6. Saudi Arabia Vinpocetine Market
- 6.5.6.1. Market Size and Forecast, By Product Type
- 6.5.6.2. Market Size and Forecast, By Distribution Channel
- 6.5.7. South Africa Vinpocetine Market
- 6.5.7.1. Market Size and Forecast, By Product Type
- 6.5.7.2. Market Size and Forecast, By Distribution Channel
- 6.5.8. Rest of LAMEA Vinpocetine Market
- 6.5.8.1. Market Size and Forecast, By Product Type
- 6.5.8.2. Market Size and Forecast, By Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
- 8.1. Northeast Pharmaceutical Group Co., Ltd.
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
- 8.2. COVEX
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
- 8.3. Runhong
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
- 8.4. Liaoning Zhiying
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
- 8.5. Sun Pharmaceuticals Industries Ltd
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
- 8.6. Welman
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Micro Labs Ltd
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
- 8.8. Gedeon Richter Plc.
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
